BRIEF-Immunocellular receives regulatory nod to start ICT-107 phase 3 trial
May 06, 2016 at 06:15 AM EDT
* Receives regulatory approval in Canada, the UK and the Netherlands to initiate ICT-107 Phase 3 trial in newly diagnosed glioblastoma